Abstract: The present invention provides lifitegrast formulations useful for the treatment of immune-related diseases of the ocular surface. The formulations and methods provided herein are particularly useful for treatment of ocular anterior segment tissues.

Abstract: Disclosed are methods of preventing or treating a disease or adverse condition affecting the gastrointestinal tract of a mammal which comprise orally administering to a mammal a therapeutically effective amount of a prodrug of a proton pump inhibitor and an effective amount of a trefoil family factor peptide, mucoadhesive agent, or a combination thereof. Also disclosed are compositions which are suitable for use in a pharmaceutical dosage form. These compositions comprise a prodrug of a proton pump inhibitor, and also comprise a trefoil family factor peptide, a mucoadhesive component, or a combination thereof.

Abstract: Biocompatible microparticles include a ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-oil emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

Abstract: Oral dosage forms, methods of treating diseases or adverse conditions, and methods of inhibiting gastric acid secretion related to prodrugs of a proton pump inhibitor are disclosed herein. Certain embodiments relate to the membrane permeability of the proton pump inhibitor and/or the membrane permeability of the prodrug. Other embodiments relate to prodrugs comprising an acidic functional group and a sulfonyl moiety. In other embodiments, the prodrug is a carboxylic acid which comprises a phenylsulfonyl moiety. Other embodiments relate to the pH of dosage forms and dosage forms comprising salts of acidic functional groups.